MedPath

A prospective observational study on the efficacy of switching to sertraline in depressive patients who failed treatment with duloxetine

Not Applicable
Recruiting
Conditions
major depressive disorder
Registration Number
JPRN-UMIN000009609
Lead Sponsor
Tokyo Womens Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Comorbidity of alcohol and/or drug abuse Presence of psychosis Intolerant to sertraline Required prohibited concomitant therapy (to be described) Pregnant women women suspected of being pregnant or breastfeeding Serious or unstable medical illness Judged to be at risk by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy rate of switching from duloxetine to sertraline using CGI-I, HAM-D, patient rating scales (CES-D)
Secondary Outcome Measures
NameTimeMethod
Epigenetic changes before and after sertraline treatment Baseline clinical, genetic, and epigenetic and metabolome factors in sertraline responders compared to those of non-responders Baseline clinical, genetic, and epigenetic and metabolome factors in sertraline remitters compared to those of non-remitters
© Copyright 2025. All Rights Reserved by MedPath